Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)
CNY 9.08
(12.24%)
CNY 9.08
(12.24%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 289.57 Million CNY | -38.62% |
| 2022 | 447.54 Million CNY | -5.31% |
| 2021 | 472.66 Million CNY | 35.99% |
| 2020 | 347.56 Million CNY | -40.14% |
| 2019 | 580.61 Million CNY | -20.6% |
| 2018 | 731.27 Million CNY | -44.22% |
| 2017 | 1.31 Billion CNY | -1.64% |
| 2016 | 1.33 Billion CNY | 12.93% |
| 2015 | 1.18 Billion CNY | 14.39% |
| 2014 | 1.03 Billion CNY | 21.56% |
| 2013 | 848.68 Million CNY | 60.98% |
| 2012 | 527.19 Million CNY | 188.77% |
| 2011 | 182.56 Million CNY | 60.31% |
| 2010 | 113.88 Million CNY | 52.05% |
| 2009 | 74.9 Million CNY | 86.51% |
| 2008 | 40.16 Million CNY | 155.87% |
| 2007 | 15.69 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 65.52 Million CNY | -16.27% |
| 2024 Q3 | 63.35 Million CNY | -3.31% |
| 2024 Q1 | 78.25 Million CNY | 12.62% |
| 2023 FY | 274.7 Million CNY | -38.62% |
| 2023 Q1 | 54.6 Million CNY | -60.17% |
| 2023 Q2 | 86 Million CNY | 57.49% |
| 2023 Q4 | 69.48 Million CNY | -17.01% |
| 2023 Q3 | 83.72 Million CNY | -2.64% |
| 2022 Q4 | 137.08 Million CNY | 24.47% |
| 2022 FY | 447.54 Million CNY | -5.31% |
| 2022 Q1 | 95.11 Million CNY | -25.06% |
| 2022 Q2 | 105.21 Million CNY | 10.62% |
| 2022 Q3 | 110.13 Million CNY | 4.67% |
| 2021 Q2 | 128.06 Million CNY | 35.35% |
| 2021 Q1 | 94.62 Million CNY | -8.05% |
| 2021 FY | 472.66 Million CNY | 35.99% |
| 2021 Q4 | 126.92 Million CNY | 3.14% |
| 2021 Q3 | 123.05 Million CNY | -3.92% |
| 2020 FY | 347.56 Million CNY | -40.14% |
| 2020 Q4 | 102.9 Million CNY | -6.19% |
| 2020 Q3 | 109.7 Million CNY | 21.54% |
| 2020 Q2 | 90.25 Million CNY | 101.92% |
| 2020 Q1 | 44.69 Million CNY | -62.1% |
| 2019 FY | 580.61 Million CNY | -20.6% |
| 2019 Q3 | 157.16 Million CNY | 2.89% |
| 2019 Q4 | 117.95 Million CNY | -24.95% |
| 2019 Q2 | 152.74 Million CNY | -0.01% |
| 2019 Q1 | 152.75 Million CNY | -0.99% |
| 2018 FY | 731.27 Million CNY | -44.22% |
| 2018 Q1 | 252.03 Million CNY | -11.01% |
| 2018 Q4 | 154.28 Million CNY | -9.13% |
| 2018 Q3 | 169.78 Million CNY | 9.42% |
| 2018 Q2 | 155.16 Million CNY | -38.44% |
| 2017 Q4 | 283.22 Million CNY | -20.06% |
| 2017 Q1 | 313.96 Million CNY | -16.09% |
| 2017 Q2 | 359.43 Million CNY | 14.48% |
| 2017 Q3 | 354.3 Million CNY | -1.43% |
| 2017 FY | 1.31 Billion CNY | -1.64% |
| 2016 FY | 1.33 Billion CNY | 12.93% |
| 2016 Q1 | 262.49 Million CNY | -21.52% |
| 2016 Q4 | 374.16 Million CNY | 0.03% |
| 2016 Q2 | 322.03 Million CNY | 22.68% |
| 2016 Q3 | 374.05 Million CNY | 16.15% |
| 2015 Q3 | 319.26 Million CNY | 4.24% |
| 2015 FY | 1.18 Billion CNY | 14.39% |
| 2015 Q4 | 334.47 Million CNY | 4.77% |
| 2015 Q2 | 306.27 Million CNY | 39.12% |
| 2015 Q1 | 220.14 Million CNY | -23.26% |
| 2014 Q4 | 286.86 Million CNY | 4.1% |
| 2014 FY | 1.03 Billion CNY | 21.56% |
| 2014 Q1 | 205.28 Million CNY | -14.08% |
| 2014 Q2 | 263.95 Million CNY | 28.58% |
| 2014 Q3 | 275.56 Million CNY | 4.4% |
| 2013 Q3 | 217.63 Million CNY | 1.1% |
| 2013 Q4 | 238.92 Million CNY | 9.78% |
| 2013 FY | 848.68 Million CNY | 60.98% |
| 2013 Q1 | 176.86 Million CNY | -17.76% |
| 2013 Q2 | 215.25 Million CNY | 21.71% |
| 2012 Q1 | 61.57 Million CNY | -9.03% |
| 2012 Q4 | 215.07 Million CNY | 38.54% |
| 2012 Q2 | 95.29 Million CNY | 54.77% |
| 2012 Q3 | 155.24 Million CNY | 62.9% |
| 2012 FY | 527.19 Million CNY | 188.77% |
| 2011 Q1 | 27.33 Million CNY | -27.42% |
| 2011 FY | 182.56 Million CNY | 60.31% |
| 2011 Q3 | 47.37 Million CNY | 17.92% |
| 2011 Q4 | 67.68 Million CNY | 42.88% |
| 2011 Q2 | 40.17 Million CNY | 46.96% |
| 2010 Q2 | 26 Million CNY | 10.07% |
| 2010 FY | 113.88 Million CNY | 52.05% |
| 2010 Q3 | 27.08 Million CNY | 4.16% |
| 2010 Q1 | 23.62 Million CNY | 0.0% |
| 2010 Q4 | 37.66 Million CNY | 39.03% |
| 2009 FY | 74.9 Million CNY | 86.51% |
| 2008 FY | 40.16 Million CNY | 155.87% |
| 2007 FY | 15.69 Million CNY | 0.0% |